MedTrace Logo

The Efficacy and Safety of Beta-blockers Drugs in Adults With Spinal Hemangioma

NCT05106179 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1000

Last updated 2021-11-03

No results posted yet for this study

Summary

Spinal hemangioma is one of the most common benign vertebral tumours. Being mostly asymptomatic, it is still associated with a pain syndrome especially if encroaches into the neural canal.

This study is organised to evaluate the efficacy and safety of β-blockers drugs in adults with spinal hemangioma.

Conditions

  • Spinal Tumor
  • Spinal Hemangioma
  • Beta Blocker Toxicity

Interventions

DRUG

Atenolol Pill

Atenolol is a second-generation hydrophilic β-1-selective adrenergic antagonist, which is primarily metabolised by the kidneys.

DRUG

Propranolol Pill

Propranolol is highly lipophilic, nonselective β-blockers, which is primarily metabolised by the liver.

Sponsors & Collaborators

  • Center for Vascular Pathology, Moscow

    lead OTHER

Principal Investigators

  • Ekaterina Listovskaia, MD · The Vascular Anomalies Center (VAC) "Hemangioma",

  • Dmitry Romanov, MD · The Vascular Anomalies Center (VAC) "Hemangioma"

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-31
Primary Completion
2022-12-31
Completion
2023-12-31

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05106179 on ClinicalTrials.gov